A newly diagnosed prognostic stratification system for multiple myeloma based on Myc gene translocation detection
Through the detection and quantitative scoring mechanism based on Myc gene translocation, the problem of rough evaluation of risk factor weights in the existing multiple myeloma prognostic stratification system is solved, the accuracy of prognostic stratification and system adaptability are improved, and the accuracy of prognostic stratification and system adaptability are achieved. More accurate patient risk assessment.
Patent Information
- Application Number
- CN202311493944.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-10
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-11-10
AI Technical Summary
The existing multiple myeloma prognostic stratification system has a rough evaluation of risk factors, which cannot effectively reflect the prognostic differences between different high-risk factors, affecting the accuracy of the prognostic stratification system.
A new prognosis stratification system for diagnosis of multiple myeloma based on Myc gene translocation detection is adopted. The Myc gene translocation information and other related information are obtained through the cytogenetic abnormal information acquisition module, and the judgment module is used to quantify the risk level based on this information. Scoring is divided into three-level risk levels: low-risk, medium-risk and high-risk.
Improve the accuracy of prognostic stratification of multiple myeloma, and by giving higher weights to factors such as Myc gene translocation, the flexibility and adaptability of the system are enhanced, and the accuracy of predicting patients' survival time and progress time is significantly improved. .
Smart Images

Figure CN117497046B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and more specifically, relates to a newly diagnosed multiple myeloma prognosis stratification system based on Myc gene translocation detection. Background Art
[0002] Multiple myeloma (MM) is the second most common hematological malignancy in the world, and it is more common in the elderly. As my country enters an aging society, the incidence of MM has increased year by year, greatly endangering the health and safety of the people. With the deepening of the requirements for precision and individualized treatment, MM patients are classified according to their prognosis, so that targeted treatment options can be selected to effectively improve the quality of life and reduce the pain of treatment. An ideal risk stratification system can not only match the best treatment plan for patients, but also take into account social and economic benefits and reduce the waste of medical resources. In addition, risk stratification helps to promote the optimization of treatment strategies, suggesting that clinicians can use multi-drug combined strong induction chemotherapy and active consolidation and maintenance therapy when facing high-risk patients, and that drug development focuses on gene mutations in high-risk patients and tilts towards corresponding targeted drug research, in order to further overcome the poor prognosis caused by high-risk factors.
[0003] The current mainstream risk stratification system is mainly based on biochemical indicators + cytogenetic abnormalities (gene mutations, deletions and amplifications, etc.). Different stratification systems include different indicators, and the weights assigned to the indicators may be different. The earliest ISS / RISS system divides patients into stages I, II and III by combining blood biochemical test results with FISH (fluorescence in situ hybridization technology) to check gene mutations. It can be seen that in the RISS stage, the median overall survival time of high-risk patients (stage III) is less than 2 years (43 months).
[0004] In the second risk stratification system, the mSMART3.0 system, the Mayo Center team streamlined the risk stratification and divided patients into only high-risk and low-risk patients. The median overall survival time of low-risk patients has exceeded 120 months (nearly 10 years), while that of high-risk patients is only 2-3 years.
[0005] The third risk system is different in terms of indicators. It uses a method of assigning points to each risk factor. When the total score is 0, it is defined as low risk; when the total score is 1, it is defined as medium risk; when the total score is ≥ 2 points, it is defined as a high-risk patient. The median overall survival time of patients was 54 months, 84 months, and 132 months, respectively.
[0006] The current prognostic stratification system for newly diagnosed multiple myeloma still makes a rough assessment of the weights of risk factors and cannot well reflect the prognostic differences between different high-risk factors, which affects the accuracy of the prognostic stratification system for multiple myeloma. Summary of the invention
[0007] In view of the above defects or improvement needs of the prior art, the present invention provides a newly diagnosed multiple myeloma prognosis stratification system based on Myc gene translocation detection, which aims to improve the accuracy of the prognosis stratification of newly diagnosed multiple myeloma by introducing an independent high-risk factor Myc gene translocation, thereby solving the technical problem of poor stratification accuracy of the existing prognosis stratification system for newly diagnosed multiple myeloma.
[0008] To achieve the above object, according to one aspect of the present invention, a newly diagnosed multiple myeloma prognosis stratification system based on Myc gene translocation detection is provided, which comprises: a cytogenetic abnormality information acquisition module, and a judgment module;
[0009] The cytogenetic abnormality information acquisition module is used to acquire the Myc gene translocation information of the prognostic stratification object and submit it to the judgment module;
[0010] The judgment module is used to judge the prognostic stratification of the prognostic stratification object according to the Myc gene translocation information and the principle that the prognostic stratification risk level of newly diagnosed multiple myeloma is increased when Myc gene translocation abnormality occurs.
[0011] Preferably, the cytogenetic abnormality information acquisition module of the newly diagnosed multiple myeloma prognosis stratification system based on Myc gene translocation detection is further used to obtain 17p deletion information, IgH high-risk translocation information, and / or 1q21 amplification information of the prognostic stratification object, and submit it to the judgment module;
[0012] The judgment module is used to improve the risk level of prognosis stratification of newly diagnosed multiple myeloma according to the 17p deletion information, IgH high-risk translocation information, and 1q21 amplification information;
[0013] The IgH high-risk translocation includes t(4;14) translocation and / or t(14;16) translocation.
[0014] Preferably, the cytogenetic abnormality information acquisition module of the newly diagnosed multiple myeloma prognosis stratification system based on Myc gene translocation detection is also used to obtain 17p deletion information, IgH high-risk translocation information, and 1q21 amplification information of the prognostic stratification object, and submit them to the judgment module;
[0015] The judgment module is used to perform risk stratification according to the 17p deletion information, the IgH high-risk translocation information, and the 1q21 amplification information, according to the principle that the occurrence of 17p deletion, IgH high-risk translocation, and 1q21 amplification increases the level of risk of prognostic stratification of newly diagnosed multiple myeloma.
[0016] Preferably, the judgment module of the newly diagnosed multiple myeloma prognosis stratification system based on Myc gene translocation detection adopts a scoring system to quantify the risk level, and scores according to the principle that the higher the score, the higher the risk, and divides the multiple myeloma prognosis stratification risk level into three levels, namely high risk, intermediate risk, and low risk.
[0017] Preferably, in the prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection, the quantitative scoring weights adopted by the judgment module are:
[0018] The weight ratio of Myc gene translocation information to 17p deletion information was 1.5:1;
[0019] The weight ratio of Myc gene translocation information to IgH high-risk translocation information is 3:1;
[0020] The weight ratio of Myc gene translocation information to 1q21 amplification information is 3:1.
[0021] Preferably, in the prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection, the quantitative scoring mechanism adopted by the judgment module is:
[0022] Myc translocation was 1.5 points, 17p deletion was 1 point, IgH high-risk translocation was 0.5 points, and 1q21 amplification was 0.5 points;
[0023] A comprehensive score lower than 1.0 indicates a low-risk prognostic risk for multiple myeloma; a comprehensive score higher than or equal to 1.0 and lower than 2.0 indicates a medium-risk prognostic risk for multiple myeloma; a comprehensive score higher than or equal to 2.0 indicates a high-risk prognostic risk for multiple myeloma.
[0024] Preferably, the prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection determines:
[0025] The predicted time to progression for high-risk level is 9.7-22.3 months, the predicted time to progression for intermediate-risk level is 10.8-29.0 months, and the predicted time to progression for low-risk level is 24.5-36.3 months.
[0026] Preferably, the prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection determines:
[0027] The predicted time to progression for high-risk level is 16.0 months, the predicted time to progression for intermediate-risk level is 19.9 months, and the predicted time to progression for low-risk level is 30.4 months.
[0028] Preferably, the prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection determines:
[0029] The predicted survival time for high-risk level is 16.2-35.5 months, the predicted survival time for intermediate-risk level is 11.4-61.3 months, and the predicted survival time for low-risk level is 58.6-82.0 months.
[0030] Preferably, the prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection determines:
[0031] The predicted survival time for high-risk level is 25.8 months, the predicted survival time for intermediate-risk level is 36.4 months, and the predicted survival time for low-risk level is 70.3 months.
[0032] In general, the above technical solutions conceived by the present invention can achieve the following beneficial effects compared with the prior art:
[0033] The present invention provides a newly diagnosed multiple myeloma prognosis stratification system based on Myc gene translocation detection: the PUMCH-MM system innovatively incorporates Myc translocation, which has an important impact on patient survival, and finds that Myc gene translocation, rather than other abnormalities of the Myc gene, is an independent high-risk prognostic factor. Data show that the impact of Myc translocation cannot be ignored because its incidence is not low and has a negative impact on patient survival. The preferred solution determines its weight ratio with other high-risk factors, emphasizing the difference in the impact of high-risk factors on survival, so that the risk stratification system has more flexible performance capabilities when stratifying patients, and can better adapt to existing clinical diagnosis and treatment practices. Data verification shows that the area under the ROC curve (AUC) value of the PUMCH-MM system reaches 0.641, and its accuracy is significantly improved compared with the general IMWG system and MAYO system. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 is a graph showing the effect of Myc gene abnormality on the prognosis of newly diagnosed multiple myeloma patients provided in Example 1, wherein Figure 1 A is the median progression-free survival time analysis. Figure 1 B is the median overall survival time analysis;
[0035] Figure 2 is a graph showing the results of the analysis of the effects of Myc translocation, Myc amplification and other abnormalities on the prognosis of newly diagnosed multiple myeloma patients provided in Example 1, wherein Figure 2 A is the median progression-free survival time analysis. Figure 2 B is the median overall survival time analysis;
[0036] Figure 3is a subgroup survival analysis result diagram provided in Example 3, wherein Figure 3 A is the median progression-free survival analysis. Figure 3 B is the median overall survival time analysis;
[0037] Figure 4 is a graph showing the effect of four high-risk factors on the prognosis of newly diagnosed multiple myeloma patients provided in Example 3, wherein Figure 4 A is the median progression-free survival analysis. Figure 4 B is the median overall survival time analysis;
[0038] Figure 5 This is the ROC curve for internal cohort validation provided in Example 4. DETAILED DESCRIPTION
[0039] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0040] The newly diagnosed multiple myeloma prognosis stratification system based on Myc gene translocation detection provided by the present invention is characterized by comprising: a cytogenetic abnormality information acquisition module and a judgment module;
[0041] The cytogenetic abnormality information acquisition module is used to acquire the Myc gene translocation information of the prognostic stratification object and submit it to the judgment module; preferably, it is also used to acquire the 17p deletion information, IgH high-risk translocation information, and / or 1q21 amplification information of the prognostic stratification object and submit it to the judgment module;
[0042] The judgment module is used to judge the prognostic stratification of the prognostic stratification object according to the Myc gene translocation information and the principle that the prognostic stratification risk level of newly diagnosed multiple myeloma is increased if the Myc gene translocation abnormality occurs; preferably, it is used to judge the prognostic stratification of the prognostic stratification object according to the Myc gene translocation information, the 17p deletion information, the IgH high-risk translocation information, and the 1q21 amplification information and the principle that the prognostic stratification risk level of newly diagnosed multiple myeloma is increased if the 17p deletion, the IgH high-risk translocation, and the 1q21 amplification occurs; the IgH high-risk translocation includes t(4;14) translocation and / or t(14;16) translocation.
[0043] Specifically, the judgment module uses a scoring system to quantify the risk level, and scores according to the principle that the higher the score, the higher the risk, and divides the risk level of multiple myeloma prognosis stratification into three levels, namely high risk, medium risk, and low risk. The quantitative scoring weights used by the judgment module are:
[0044] The weight ratio of Myc gene translocation information to 17p deletion information was 1.5:1;
[0045] The weight ratio of Myc gene translocation information to IgH high-risk translocation information is 3:1;
[0046] The weight ratio of Myc gene translocation information to 1q21 amplification information is 3:1.
[0047] The specific mechanism is:
[0048] The quantitative scoring mechanism adopted by the judgment module is:
[0049] Myc translocation was 1.5 points, 17p deletion was 1 point, IgH high-risk translocation was 0.5 points, and 1q21 amplification was 0.5 points;
[0050] A comprehensive score lower than 1.0 indicates a low-risk prognostic risk for multiple myeloma; a comprehensive score higher than or equal to 1.0 and lower than 2.0 indicates a medium-risk prognostic risk for multiple myeloma; a comprehensive score higher than or equal to 2.0 indicates a high-risk prognostic risk for multiple myeloma.
[0051] The prognostic stratification system determines:
[0052] The predicted time for progression of high-risk patients is 9.7-22.3 months, the predicted time for progression of intermediate-risk patients is 10.8-29.0 months, and the predicted time for progression of low-risk patients is 24.5-36.3 months. The predicted survival time of high-risk patients is 16.2-35.5 months, the predicted survival time of intermediate-risk patients is 11.4-61.3 months, and the predicted survival time of low-risk patients is 58.6-82.0 months.
[0053] The predicted time to progression for high-risk patients is 16.0 months, the predicted time to progression for intermediate-risk patients is 19.9 months, and the predicted time to progression for low-risk patients is 30.4 months. The predicted survival time for high-risk patients is 25.8 months, the predicted survival time for intermediate-risk patients is 36.4 months, and the predicted survival time for low-risk patients is 70.3 months.
[0054] The following are examples:
[0055] Example 1 Effects of different Myc gene abnormalities on the prognosis of newly diagnosed multiple myeloma patients
[0056] Random testing of Myc abnormalities in more than 400 newly diagnosed multiple myeloma patients proved that Myc translocation is a high-incidence cytogenetic abnormality that cannot be ignored (the incidence in our team's cohort is 14.7%, the incidence reported by other centers internationally is between 8-20%, and the incidence of 17p deletion, which has been included in the risk stratification system, is about 8%), and 2 / 3 of Myc translocations are combined with other high-risk cytological abnormalities. Survival analysis of patients found that patients with Myc translocations rather than other abnormalities had worse survival, such as Figure 1 As shown, the red line represents Myc translocation (Myc-R), the blue line represents Myc negative (Myc-N), and the green line represents Myc other abnormalities (Myc-OA). Figure A is the progression-free survival time analysis, and Figure B is the overall survival time analysis. The test P value <0.05 is considered statistically significant:
[0057] Among Myc abnormalities, the progression-free survival and overall survival of Myc translocation, Myc amplification and other abnormalities were further compared. The results of KM survival analysis showed that the progression-free survival and overall survival of Myc translocation were poor, such as Figure 2 As shown, Figure A is the progression-free survival analysis, and Figure B is the overall survival analysis.
[0058] The above results show that for the Myc gene, compared with Myc amplification and other abnormalities, the translocation of the Myc gene has a significantly greater impact on the prognosis of newly diagnosed multiple myeloma, indicating that the Myc gene can be used as information in the prognostic stratification system of newly diagnosed multiple myeloma, thereby improving the accuracy of the multiple myeloma prognostic system.
[0059] Example 2 Myc gene translocation is an independent prognostic factor in newly diagnosed multiple myeloma
[0060] A univariate analysis of the COX proportional hazard model was performed on the Myc gene translocation: multiple factors that may affect the patient's survival (including age, gender, hemoglobin, and other indicators) were included, and meaningful indicators were screened and included in the subsequent multivariate analysis model.
[0061] The results are shown in the following table:
[0062]
[0063] #IgH high-risk translocation refers to t(4;14) and / or t(14;16)
[0064] *New drug regimens refer to those containing proteasome inhibitors and / or immunomodulators (excluding thalidomide)
[0065] In the COX univariate model, the indicators with P values < 0.05 were further incorporated into the multivariate model. The results are shown in the following table:
[0066]
[0067] The above analysis showed that Myc translocation was an independent factor with adverse prognostic significance for both PFS and OS.
[0068] Example 3
[0069] Subgroup survival analysis showed that the results Figure 3 As shown, the adverse effect of Myc translocation on patient survival has exceeded that of other cytogenetic abnormalities that have been included in risk stratification (such as 17p deletion, IgH high-risk translocation and 1q21 amplification). The red line represents patients with Myc translocation, and the blue line represents patients with other single high-risk genetic abnormalities. Both PFS (progression-free survival) and overall survival (OS) are worse than those of patients with other high-risk genetic abnormalities.
[0070] Survival analysis was further performed to compare the four high-risk genetic factors. Figure 4 As shown, the red survival curve represents patients with Myc translocation, who have the worst survival. Incorporating Myc translocation information into the influencing factors of the prognostic stratification system for newly diagnosed multiple myeloma can significantly improve the accuracy of the prognostic system.
[0071] Since Myc translocation information has higher accuracy than other high-risk factors, it is more reasonable to give Myc translocation information a higher weight when using the scoring method as a prognostic stratification system than the current stratification system that uses the same weight for all high-risk factors.
[0072] The Myc translocation information in the newly diagnosed multiple myeloma prognostic stratification system provided by this patent has the highest weight, followed by patients with 17p deletion, and IgH high-risk translocation and 1q21 amplification are close. The specific value scores assigned by the weights are: Myc translocation is 1.5 points, 17p deletion is 1 point, IgH high-risk translocation and 1q21 amplification are both 0.5 points, and no any of the above cytogenetic abnormalities is 0 points; newly diagnosed multiple myeloma patients with a score less than 1.0 are judged as low risk, newly diagnosed multiple myeloma patients with a score greater than or equal to 1.0 and less than 2.0 are judged as medium risk, and newly diagnosed multiple myeloma patients with a score greater than or equal to 2 are judged as high risk. As shown in the following table:
[0073] The risk stratification system provided in this example: PUMCH-MM
[0074] Risk factors Points Total score Prognostic stratification Median time to progression Median overall survival time 1q21 amplification 0.5 <1.0 Low risk 30.4 months 70.3 months t(4;14) 0.5 t(4;16) 0.5 ≥1.0 and <2.0 Moderate 19.9 months 36.4 months 17p deletion 1.0 Myc translocation 1.5 ≥2.0 High risk 16.0 months 25.8 months
[0075] Example 4: Verification in an internal queue
[0076] The newly diagnosed multiple myeloma prognostic stratification system based on Myc gene translocation detection provided in Example 3 (PUMCH-MM system) was validated in an internal cohort, and the results were as follows: Figure 5 As shown in the figure, the area under the ROC curve (AUC) of the PUMCH-MM system was 0.641 (p=0.006), the AUC of the IMWG system was 0.554 (p=0.291), and the AUC of the MAYO system was 0.535 (p=0.501). The system has good validation efficiency and can better distinguish patients with different risk stratifications.
[0077] The median progression-free survival time of patients in the low-risk, intermediate-risk, and high-risk groups were 30.4 months (95% confidence interval, 24.5-36.3 months), 19.9 months (95% confidence interval, 10.8-29.0 months), and 16.0 months (95% confidence interval, 9.7-22.3 months), respectively. The median overall survival time was 70.3 months (58.6-82.0 months), 36.4 months (95% confidence interval, 11.4-61.3 months), and 25.8 months (95% confidence interval, 16.2-35.5 months), respectively.
[0078] It will be easily understood by those skilled in the art that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A newly diagnosed multiple myeloma prognostic stratification system based on Myc gene translocation detection, characterized in that: include: Cytogenetic abnormality information acquisition module and judgment module; The cytogenetic abnormality information acquisition module is only used to obtain Myc gene translocation information, 17p deletion information, IgH high-risk translocation information, and 1q21 amplification information of the prognostic stratification object, and submit it to the judgment module; The judgment module is used to judge the prognostic stratification of the prognostic stratification object only based on the Myc gene translocation information, the 17p deletion information, the IgH high-risk translocation information, and the 1q21 amplification information; The judgment module uses a scoring system to quantify the risk level, and scores according to the principle that the higher the score, the higher the risk, and divides the multiple myeloma prognostic stratification risk level into three levels, namely high risk, medium risk, and low risk; The IgH high-risk translocation includes t(4;14) translocation and / or t(14;16) translocation; The quantitative scoring weights used by the judgment module are: The weight ratio of Myc gene translocation information to 17p deletion information was 1.5:1; The weight ratio of Myc gene translocation information to IgH high-risk translocation information is 3:1; The weight ratio of Myc gene translocation information to 1q21 amplification information is 3:
1.
2. The prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection according to claim 1, characterized in that: The quantitative scoring mechanism adopted by the judgment module is: Myc translocation was 1.5 points, 17p deletion was 1 point, IgH high-risk translocation was 0.5 points, and 1q21 amplification was 0.5 points; A comprehensive score lower than 1.0 indicates a low-risk prognostic risk for multiple myeloma; a comprehensive score higher than or equal to 1.0 and lower than 2.0 indicates a medium-risk prognostic risk for multiple myeloma; a comprehensive score higher than or equal to 2.0 indicates a high-risk prognostic risk for multiple myeloma.
3. The prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection according to claim 2, characterized in that: The prognostic stratification system determines: The predicted time to progression for high-risk level is 9.7-22.3 months, the predicted time to progression for intermediate-risk level is 10.8-29.0 months, and the predicted time to progression for low-risk level is 24.5-36.3 months.
4. The prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection according to claim 3, characterized in that: The prognostic stratification system determines: The predicted time to progression for high-risk level is 16.0 months, the predicted time to progression for intermediate-risk level is 19.9 months, and the predicted time to progression for low-risk level is 30.4 months.
5. The prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection according to claim 2, characterized in that: The prognostic stratification system determines: The predicted survival time for high-risk level is 16.2-35.5 months, the predicted survival time for intermediate-risk level is 11.4-61.3 months, and the predicted survival time for low-risk level is 58.6-82.0 months.
6. The prognostic stratification system for newly diagnosed multiple myeloma based on Myc gene translocation detection according to claim 5, characterized in that: The prognostic stratification system determines: The predicted survival time for high-risk level is 25.8 months, the predicted survival time for intermediate-risk level is 36.4 months, and the predicted survival time for low-risk level is 70.3 months.
